Table 5.
Gastrointestinal (GI) events occurring during the 12 months (or time of study discontinuation, if earlier than 12 months) following initiation of exenatide twice daily (BID) and insulin in patients with type 2 diabetes mellitus – initiators population
| Variable | Exenatide BID (n = 1096) | Insulin (n = 1239) |
|---|---|---|
| Patients with ≥1 GI symptom, | 305 (27.8) | 43 (3.5) |
| n (%) | ||
| 1 symptom | 186 (17.0) | 28 (2.3) |
| 2 symptoms | 67 (6.1) | 8 (0.6) |
| 3 symptoms | 29 (2.6) | 5 (0.4) |
| ≥ 4 symptoms | 23 (2.1) | 2 (0.2) |
| Type of GI event, n (%) | ||
| Nausea | 165 (15.1) | 7 (0.6) |
| Abdominal pain | 62 (5.7) | 21 (1.7) |
| Fullness/early satiety | 68 (6.2) | 5 (0.4) |
| Vomiting | 62 (5.7) | 3 (0.2) |
| Heartburn | 41 (3.7) | 15 (1.2) |
| Anorexia | 22 (2.0) | 1 (0.1) |
| Taste changes | 11 (1.0) | 1 (0.1) |